ECDC Director Marc Sprenger and WHO/Europe Regional Director Zsuzsanna Jakab have signed an Administrative Agreement between ECDC and WHO/Europe during the 8th Senior Officials Meeting of the European Commission (EC) and World Health Organisation (WHO), held in Brussels on 24-25 March 2011.
This paper describes a small retrospective observational study of Israeli travellers presenting to a tropical medicine clinic with a history of prolonged (4 weeks), non-traumatic arthralgia or arthritis over a 5 year period.
IGRAs are increasingly being considered for the diagnosis of LTBI, as a replacement to the TST, including travel medicine. As with the TST, many uncertainties remain with regard to the efficacy of the IGRAs. It is therefore essential to secure an accurate understanding of these assays‘ known efficacy, so that they be optimally used and only in context with proven effect.
Few and limited occasions of dengue virus transmission have recently been reported in Europe, which were not unexpected considering the presence of the vector Aedes albopictus
Travel patterns are an important source of information to be considered when assessing the risk of spread of infectious disease outbreaks. However, local and regional particularities need to be taken into account.
The overall objective is to improve early detection and response to outbreak of zoonotic diseases at the EU level through strengthened collaboration with the animal health sector and other agencies and organizations working at the animal-human interface.
This paper serves as a gateway review of several field and epidemiological investigations conducted across the United States (US) which have been compiled as a special supplement in a January 2011 number of the Clinical Infectious Diseases journal.
This study updates previous work on modelling the incidence of varicella and Herpes Zoster (HZ) following the introduction of childhood varicella vaccination.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.